%20(1).svg)
.png)
Video Part 2 - Crucial Considerations for Clinic-Ready ASD Product Design
Formulation development of ASDs focuses on polymer selection, the ratio of drug to polymer, and the design of the ASD particles to develop a system that is physically stable while also demonstrating optimal performance. Performance of an ASD is defined by enhancement in bioavailability which is driven by both supersaturation of dissolved drug and the formation of drug-polymer colloids.
In this 2nd half of our two-part presentation, Dr. Tatum explores the interplay of drug product intermediate and drug product design on performance through a case study of ASD formulations.
Learning Objectives:
• ASD Product (Tablet) Design
o Considering TPP / Product Design in ASD screening
o Considering impact of particle properties (SDD vs HME) in product design & performance
About Serán
Serán BioScience, LLC, is a science-driven Drug Development Partner, recognized as a world leader in drug development. Utilizing a foundation of physical and chemical science, Serán designs robust formulations and engineered solutions to some of the industry's toughest drug product problems. Our experience and background cover a wide range of pharmaceutical manufacturing concepts bringing our world-class expertise to you and your drug product. Serán’s team has decades of experience developing complex drug molecules into enabling medicines. With every addition to our team, we further our commitment to our clients’ success. From preclinical to GMP and beyond, Serán is here to support you and your drug product every step of the way.
For more information, visit www.Seranbio.com or email us at hello@seranbio.com.
Contact
Serán BioScience, LLC
63047 Layton Ave, Bend, OR 97701 USA
www.seranbio.com
.svg)